Corrado Advisors LLC Sells 3,896 Shares of Harrow Health, Inc. (NASDAQ:HROW)

Corrado Advisors LLC trimmed its holdings in shares of Harrow Health, Inc. (NASDAQ:HROW) by 27.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 10,521 shares of the company’s stock after selling 3,896 shares during the period. Corrado Advisors LLC’s holdings in Harrow Health were worth $118,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Kennedy Capital Management LLC bought a new position in Harrow Health during the 3rd quarter valued at about $1,750,000. Jump Financial LLC bought a new position in shares of Harrow Health in the third quarter worth about $1,038,000. Braidwell LP raised its stake in shares of Harrow Health by 24.5% in the third quarter. Braidwell LP now owns 1,808,684 shares of the company’s stock worth $25,991,000 after acquiring an additional 356,146 shares during the last quarter. Stifel Financial Corp bought a new position in shares of Harrow Health in the third quarter worth about $4,887,000. Finally, Rice Hall James & Associates LLC bought a new position in shares of Harrow Health in the third quarter worth about $3,598,000. 72.76% of the stock is owned by institutional investors.

Harrow Health Trading Down 2.6 %

NASDAQ HROW traded down $0.28 during trading on Tuesday, reaching $10.32. 661,080 shares of the stock traded hands, compared to its average volume of 443,815. The firm has a market cap of $364.92 million, a price-to-earnings ratio of -13.76 and a beta of 0.48. The stock’s 50-day moving average price is $11.60 and its 200 day moving average price is $11.30. The company has a quick ratio of 2.61, a current ratio of 2.83 and a debt-to-equity ratio of 2.60. Harrow Health, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $28.25.

Harrow Health (NASDAQ:HROW) last issued its quarterly earnings data on Tuesday, March 19th. The company reported ($0.27) earnings per share (EPS) for the quarter. The firm had revenue of $36.36 million for the quarter, compared to analyst estimates of $37.65 million. Harrow Health had a negative net margin of 18.75% and a negative return on equity of 29.48%. Analysts predict that Harrow Health, Inc. will post -0.39 EPS for the current year.

Insider Buying and Selling at Harrow Health

In related news, major shareholder Opaleye Management Inc. purchased 50,600 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were purchased at an average price of $9.65 per share, with a total value of $488,290.00. Following the completion of the purchase, the insider now owns 3,695,600 shares in the company, valued at approximately $35,662,540. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In other Harrow Health news, major shareholder Opaleye Management Inc. acquired 50,600 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were acquired at an average price of $9.65 per share, with a total value of $488,290.00. Following the completion of the transaction, the insider now directly owns 3,695,600 shares in the company, valued at approximately $35,662,540. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Mark L. Baum acquired 9,000 shares of the business’s stock in a transaction dated Friday, March 22nd. The stock was acquired at an average cost of $11.59 per share, for a total transaction of $104,310.00. Following the transaction, the chief executive officer now owns 2,137,525 shares of the company’s stock, valued at $24,773,914.75. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 139,000 shares of company stock valued at $1,544,064. 13.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. B. Riley dropped their target price on shares of Harrow Health from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, March 22nd. Craig Hallum assumed coverage on shares of Harrow Health in a research note on Thursday, April 11th. They issued a “buy” rating and a $24.00 target price for the company.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.